INS and obesity disorder: Strikingly, treatment with EA for only 2 weeks reduced the obesity-elevated leptin and insulin levels by 69.3% (Figure 5D) and 58.5% (Figure 5E), respectively, in obese mice, which is likely due to improved obesity and insulin resistance consistent with previous findings in this mouse model (37, 38).